Luke D. Heiland
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Luke D. Heiland has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Hannah G. Farmer
Department of Otolaryngology–Head and Neck Surgery Medical University of South Carolina Charleston South Carolina USA
2 shared publicationsRodney J. Schlosser
Department of Otolaryngology–Head and Neck Surgery Medical University of South Carolina Charleston South Carolina USA
2 shared publications- Shaun A. Nguyen
Department of Otolaryngology–Head and Neck Surgery Medical University of South Carolina Charleston South Carolina USA
2 shared publications - Alejandro R. Marrero-Gonzalez
Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston, USA
1 shared publication Johnny M. Owen
Department of Otolaryngology–Head and Neck Surgery Medical University of South Carolina Charleston South Carolina USA
1 shared publication- Joshua B. Smith
Department of Otolaryngology-Head and Neck Surgery, Saint Louis University School of Medicine, St. Louis, MO 63104, USA
1 shared publication
Latest Publications
- 23 July 2025
- Published by Elsevier in Oral Oncology
- Vol. 168, 107540
Using crowdsourcing to assess HPV knowledge, behaviors, and attitudes in the United States
- 23 July 2025
- Published by Elsevier in Oral Oncology
- Vol. 168, 107540
Using crowdsourcing to assess HPV knowledge, behaviors, and attitudes in the United States
- 19 June 2024
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 171 (5) , 1308-1320
Headache and Facial Pain/Pressure in the Chronic Rhinosinusitis Population: A Systematic Review and Meta‐analysis
Objective: To evaluate the severity and prevalence of headache and facial pain/pressurere in the chronic rhinosinusitis (CRS) population. Data Sources: CINAHL, PubMed, Scopus. Review Methods: The literature was searched from inception through June 2023 for English language articles documenting “headache” or “facial pain/pressure” and “chronic rhinosinusitis.” Data collected included Lund‐MacKay computed tomography score, Lund‐Kennedy endoscopy score, sinonasal outcome test, and visual analog scale. Meta‐analyses were performed on continuous measures (mean), proportions (%), and regression. Results: A total of 69 studies were included with 8643 CRS patients and 703 control patients. The CRS group had a mean age of 44.1 (range: 16‐82; 95% confidence interval [CI]: 40.3‐48) and 86.1% [95% CI: 76.4‐93.5] with nasal polyposis. The control group had a mean age of 39.2 (range: 17‐88; 95% CI: 28.7‐49.8). All CRS subgroups had significantly more severe headache and facial pain/pressure when compared to the control ( P < .0001). Patients without polyps had significantly more severe facial pain/pressure and headache when compared to patients with polyps ( P < .0001). Facial pain/pressure is a moderate problem or worse in 29.8% of polypoid patients versus 56.4% of nonpolypoid patients; Δ26.6% [95% CI: 0.7‐50; P = .045]. Conclusions: Across all outcome metrics, CRS patients experience significantly more severe headache and facial pain/pressure when compared to a control population. Nonpolypoid patients experience significantly more severe facial pain/pressure and headache when compared to polypoid patients. The majority of nonpolypoid patients experience facial pain/pressure that is moderate in severity or worse.
- 19 June 2024
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 171 (5) , 1308-1320
Headache and Facial Pain/Pressure in the Chronic Rhinosinusitis Population: A Systematic Review and Meta‐analysis
Objective: To evaluate the severity and prevalence of headache and facial pain/pressurere in the chronic rhinosinusitis (CRS) population. Data Sources: CINAHL, PubMed, Scopus. Review Methods: The literature was searched from inception through June 2023 for English language articles documenting “headache” or “facial pain/pressure” and “chronic rhinosinusitis.” Data collected included Lund‐MacKay computed tomography score, Lund‐Kennedy endoscopy score, sinonasal outcome test, and visual analog scale. Meta‐analyses were performed on continuous measures (mean), proportions (%), and regression. Results: A total of 69 studies were included with 8643 CRS patients and 703 control patients. The CRS group had a mean age of 44.1 (range: 16‐82; 95% confidence interval [CI]: 40.3‐48) and 86.1% [95% CI: 76.4‐93.5] with nasal polyposis. The control group had a mean age of 39.2 (range: 17‐88; 95% CI: 28.7‐49.8). All CRS subgroups had significantly more severe headache and facial pain/pressure when compared to the control ( P < .0001). Patients without polyps had significantly more severe facial pain/pressure and headache when compared to patients with polyps ( P < .0001). Facial pain/pressure is a moderate problem or worse in 29.8% of polypoid patients versus 56.4% of nonpolypoid patients; Δ26.6% [95% CI: 0.7‐50; P = .045]. Conclusions: Across all outcome metrics, CRS patients experience significantly more severe headache and facial pain/pressure when compared to a control population. Nonpolypoid patients experience significantly more severe facial pain/pressure and headache when compared to polypoid patients. The majority of nonpolypoid patients experience facial pain/pressure that is moderate in severity or worse.
- 10 May 2024
- Published by Wiley in The Laryngoscope
- Vol. 134 (11) , 4458-4465
Medical Management of Headache and Facial Pain in CRS: A Systematic Review and Meta‐Analysis
Objectives: This study aims to characterize the effect of medical therapy on headache and facial pain/pressure among patients with chronic rhinosinusitis (CRS).Data Sources: CINAHL, PubMed, and Scopus.Methods: CINAHL, PubMed, and Scopus were searched from inception through April 10th, 2024, for English language articles reporting headache or facial pain/pressure outcomes in CRS patients. Inclusion was restricted to studies reporting results of the medical treatment of CRS in nonsurgical cohorts. Primary outcome measures included the sino‐nasal outcome test (SNOT) and the visual analogue scale (VAS). Meta‐analyses of continuous measures (mean), mean difference (Δ), and proportions (%) were conducted.Results: The initial search yielded 2429 unique articles. After a full‐text review of 272 articles, 17 studies reporting outcomes for 2269 patients were included in the meta‐analysis. The mean patient age was 48.6 years (range 18.0–86.0; 95% CI: 46.5 to 50.6), among which 55.4% (95% CI: 51.5 to 59.4) were male and 82.9% (95% CI: 68.8 to 93.4) had nasal polyposis. SNOT facial pain/pressure scores improved by 1.1 points (95% CI: −1.7 to −0.5; relative reduction 40.4%) with non‐biologic therapies and 1.0 point (95% CI: −1.4 to −0.6; relative reduction 54.6%) with biologic therapies. On an 11‐point scale, VAS headaches scores improved by 1.8 units (95% CI: −3.3 to −0.3; 42.1% relative reduction) in CRSwNP patients and 1.0 unit (95% CI: −1.7 to −0.3; 54.0% relative reduction) in CRSsNP patients.Conclusions: Our findings suggest medical therapy significantly reduces facial pain and pressure in the CRS population. Laryngoscope, 134:4458–4465, 2024
- 10 May 2024
- Published by Wiley in The Laryngoscope
- Vol. 134 (11) , 4458-4465
Medical Management of Headache and Facial Pain in CRS: A Systematic Review and Meta‐Analysis
Objectives: This study aims to characterize the effect of medical therapy on headache and facial pain/pressure among patients with chronic rhinosinusitis (CRS).Data Sources: CINAHL, PubMed, and Scopus.Methods: CINAHL, PubMed, and Scopus were searched from inception through April 10th, 2024, for English language articles reporting headache or facial pain/pressure outcomes in CRS patients. Inclusion was restricted to studies reporting results of the medical treatment of CRS in nonsurgical cohorts. Primary outcome measures included the sino‐nasal outcome test (SNOT) and the visual analogue scale (VAS). Meta‐analyses of continuous measures (mean), mean difference (Δ), and proportions (%) were conducted.Results: The initial search yielded 2429 unique articles. After a full‐text review of 272 articles, 17 studies reporting outcomes for 2269 patients were included in the meta‐analysis. The mean patient age was 48.6 years (range 18.0–86.0; 95% CI: 46.5 to 50.6), among which 55.4% (95% CI: 51.5 to 59.4) were male and 82.9% (95% CI: 68.8 to 93.4) had nasal polyposis. SNOT facial pain/pressure scores improved by 1.1 points (95% CI: −1.7 to −0.5; relative reduction 40.4%) with non‐biologic therapies and 1.0 point (95% CI: −1.4 to −0.6; relative reduction 54.6%) with biologic therapies. On an 11‐point scale, VAS headaches scores improved by 1.8 units (95% CI: −3.3 to −0.3; 42.1% relative reduction) in CRSwNP patients and 1.0 unit (95% CI: −1.7 to −0.3; 54.0% relative reduction) in CRSsNP patients.Conclusions: Our findings suggest medical therapy significantly reduces facial pain and pressure in the CRS population. Laryngoscope, 134:4458–4465, 2024
- 14 February 2024
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 170 (5) , 1234-1245
Neuromodulation for Treatment of Tinnitus: A Systematic Review and Meta‐Analysis
Objective: To evaluate the treatment efficacy of neuromodulation versus sham for the treatment of tinnitus.Data Sources: Cochrane Library, CINAHL, PubMed, Scopus.Review Methods: The Cochrane Library, CINAHL, PubMed, and Scopus were searched from inception through May 2023 for English language articles documenting “neuromodulation” and “tinnitus” stratified by sham‐controlled randomized control trials with 40 or more patients. Data collected included Beck Anxiety Inventory, Beck Depression Inventory (BDI), Tinnitus Handicap Inventory (THI), Tinnitus Questionnaire, and Visual Analog Scale. A Meta‐analysis of continuous measures (mean) and proportions (%) were conducted.Results: A total of 19 randomized control trials (N = 1186) were included. The mean age was 48.4 ± 5.3 (range: 19‐74), mean duration of tinnitus was 3.8 ± 3.4 years, 61% [56.2‐65.7] male, and 55.7% [46‐65] with unilateral tinnitus. The short‐term effect of transcutaneous electrical nerve stimulation and transcranial direct current stimulation on THI score is −16.2 [−23.1 to −9.3] and −19 [−30.1 to −7.8], respectively. The long‐term effect of repetitive transcranial magnetic stimulation on THI score is −8.6 [−11.5 to −5.7]. Transcranial direct current stimulation decreases BDI score by −11.8 [−13.3 to −10.3].Conclusion: As measured by the Tinnitus Handicap Index, our findings suggest the effects of transcutaneous electrical nerve stimulation and transcranial direct current stimulation reach significant benefit in the short term, whereas repetitive transcranial magnetic stimulation reaches significant benefit in the long term. Based on the BDI, transcranial direct current stimulation significantly reduces comorbid depression in patients with tinnitus.
- 14 February 2024
- Published by Wiley in Otolaryngology–Head and Neck Surgery
- Vol. 170 (5) , 1234-1245
Neuromodulation for Treatment of Tinnitus: A Systematic Review and Meta‐Analysis
Objective: To evaluate the treatment efficacy of neuromodulation versus sham for the treatment of tinnitus.Data Sources: Cochrane Library, CINAHL, PubMed, Scopus.Review Methods: The Cochrane Library, CINAHL, PubMed, and Scopus were searched from inception through May 2023 for English language articles documenting “neuromodulation” and “tinnitus” stratified by sham‐controlled randomized control trials with 40 or more patients. Data collected included Beck Anxiety Inventory, Beck Depression Inventory (BDI), Tinnitus Handicap Inventory (THI), Tinnitus Questionnaire, and Visual Analog Scale. A Meta‐analysis of continuous measures (mean) and proportions (%) were conducted.Results: A total of 19 randomized control trials (N = 1186) were included. The mean age was 48.4 ± 5.3 (range: 19‐74), mean duration of tinnitus was 3.8 ± 3.4 years, 61% [56.2‐65.7] male, and 55.7% [46‐65] with unilateral tinnitus. The short‐term effect of transcutaneous electrical nerve stimulation and transcranial direct current stimulation on THI score is −16.2 [−23.1 to −9.3] and −19 [−30.1 to −7.8], respectively. The long‐term effect of repetitive transcranial magnetic stimulation on THI score is −8.6 [−11.5 to −5.7]. Transcranial direct current stimulation decreases BDI score by −11.8 [−13.3 to −10.3].Conclusion: As measured by the Tinnitus Handicap Index, our findings suggest the effects of transcutaneous electrical nerve stimulation and transcranial direct current stimulation reach significant benefit in the short term, whereas repetitive transcranial magnetic stimulation reaches significant benefit in the long term. Based on the BDI, transcranial direct current stimulation significantly reduces comorbid depression in patients with tinnitus.
- Open Access
- 16 June 2021
- Published by SAGE Publications in Ear, Nose & Throat Journal
- Vol. 102 (10) , NP518-NP521
Functional Olfactory Neuroblastoma Inducing Symptomatic SIADH
Olfactory neuroblastoma (ONB) is a rare malignancy of the sinonasal cavity, originating from neuroepithelial olfactory cells. Olfactory neuroblastoma can be difficult to diagnose due to its anatomic position and variable symptomatic presentation, leading to diagnosis at a more advanced stage. Here, we present the case of a 35-year-old man with no previous medical history who had a bicycle accident secondary to syncope. He was found to be hyponatremic and suspected to have syndrome of inappropriate antidiuretic hormone secretion (SIADH). In the workup of SIADH, a brain magnetic resonance imaging revealed a mass in the left middle meatus. The lesion secreted inappropriate amounts of ADH, resulting in symptomatic paraneoplastic SIADH. This ultimately led to the early recognition and successful resection of this rare ONB. The patient has remained disease-free for over 5 years. This case is a fortunate example of a functional malignancy of the sinonasal tract that was discovered early and successfully treated as a result of symptomatic SIADH.
- 16 June 2021
- Published by SAGE Publications in Ear, Nose & Throat Journal
- Vol. 102 (10) , NP518-NP521
Open AccessFunctional Olfactory Neuroblastoma Inducing Symptomatic SIADH
Olfactory neuroblastoma (ONB) is a rare malignancy of the sinonasal cavity, originating from neuroepithelial olfactory cells. Olfactory neuroblastoma can be difficult to diagnose due to its anatomic position and variable symptomatic presentation, leading to diagnosis at a more advanced stage. Here, we present the case of a 35-year-old man with no previous medical history who had a bicycle accident secondary to syncope. He was found to be hyponatremic and suspected to have syndrome of inappropriate antidiuretic hormone secretion (SIADH). In the workup of SIADH, a brain magnetic resonance imaging revealed a mass in the left middle meatus. The lesion secreted inappropriate amounts of ADH, resulting in symptomatic paraneoplastic SIADH. This ultimately led to the early recognition and successful resection of this rare ONB. The patient has remained disease-free for over 5 years. This case is a fortunate example of a functional malignancy of the sinonasal tract that was discovered early and successfully treated as a result of symptomatic SIADH.